This trial is active, not recruiting.

Condition asthma
Treatments soy isoflavone supplement, placebo
Phase phase 4
Sponsor American Lung Association Asthma Clinical Research Centers
Collaborator National Institutes of Health (NIH)
Start date March 2010
End date February 2014
Trial size 380 participants
Trial identifier NCT01052116, ALAACRC-10, R01 HL0088367-01A2, RO1HL087987-01A2


The trial is designed to study the effects of soy supplements on asthma control.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator)
Primary purpose treatment
(Active Comparator)
Oral isoflavone supplement (100 mg/day)
soy isoflavone supplement Soy supplement
Oral soy isoflavone supplement (100 mg/day)
(Placebo Comparator)
Matching placebo

Primary Outcomes

FEV1 assessed by forced expiratory spirometry before and after two inhalations of albuterol
time frame: -4 weeks, 0 weeks, and every 4 weeks for 6 months

Secondary Outcomes

Exhaled Nitric Oxide
time frame: Every 4 weeks for 6 months
Asthma control as measured with the Juniper Asthma Control Questionnaire (ACQ)
time frame: -4 weeks, 0 weeks, and every 4 weeks for 6 months
Asthma diary
time frame: Daily for 6 months
Episodes of poor asthma control (EPAC)
time frame: Every 4 weeks for 6 months
Increased use of bronchodilator rescue medicine over baseline
time frame: Every 4 weeks for 6 months
Asthma Symptom Utility Index (ASUI)
time frame: Every 4 weeks for 6 months
Asthma specific and generic health-related quality of life
time frame: Every 4 weeks for 6 months
Airway reactivity as measured with methacholine challenge testing
time frame: -4 weeks if necessary
Side effects and toxicity
time frame: Every 4 weeks for 6 months
Genistein levels
time frame: 0 weeks, 4 weeks, 24 weeks
Peripheral blood eosinophil counts
time frame: 0 weeks, 4 weeks, 24 weeks
Interleukin-6 (IL-6) and C-Reactive Protein (CRP)
time frame: 0 weeks, 4 weeks, 24 weeks
Urinary LTE4 levels
time frame: 0 weeks, 4 weeks, 24 weeks
Genotyping to determine genetic determinants of soy isoflavone effects (optional for participation)
time frame: 0 weeks

Eligibility Criteria

Male or female participants at least 12 years old.

Inclusion Criteria: - Age 12 or older - Physician diagnosed asthma - FEV1 equal or greater than 50% predicted pre-bronchodilator - At least 12% increase in FEV1 15-3 minutes after inhaling 2-4 puffs of albuterol or positive methacholine challenge (20% fall in FEV1 at less than 8 mg/mL). Either of these can be available from the previous 2 years - Currently prescribed daily controller asthma medication - Poor asthma control (at least one of the following) - A score of 1.5 or greater on the Juniper Asthma Control Questionnaire - Use of beta-agonist for asthma symptoms two or more times per week - Nocturnal awakening with asthma symptoms more than once per week - Two or more episodes of asthma symptoms in the past 12 months with each requiring at least one of the following: emergency department visit, unscheduled physician visit, prednisone course, hospitalization - Smoking status - Non-smoker for 6 months or longer - Less than 10 pack-years smoking history Exclusion Criteria: - Pulmonary function - FEV1 less than 50% predicted pre-bronchodilator - Other major chronic illnesses - Conditions which in the judgment of the study physician would interfere with participation in the study, e.g., non-skin cancer, endocrine disease, coronary artery disease, severe hypertension, immunodeficiency states - History of thyroid disease, breast cancer, ovarian, or endometrial cancer - History of physician diagnosis of chronic bronchitis, emphysema, or COPD - Medication use - Current consumption of soy isoflavone supplements - Oral corticosteroid use within the past 6 weeks - Use of tamoxifen - Use of an investigational treatment in the previous 30 days - "Drug" allergy - Known adverse reaction to genistein, other phytoestrogens, or soy products - Females of childbearing potential - Pregnant or lactating. Participants must agree to use effective contraception during the trial. - Non-adherence - Inability or unwillingness to provide consent or, in the case of children, inability or unwillingness of the child to provide assent - Inability to swallow study medication - Inability to perform baseline measurements - Completion of less than 10 of the last 14 days diary entries during screening period - Inability to be contacted by telephone - Intention to move out of the area within 6 months - Other - Recent asthma exacerbation (within 6 weeks) - Recent upper respiratory infection (within 2 weeks) - Body weight less than 77 pounds (35 kg) - Intake of soy or soy-enriched foods 1 or more times a week - Change in diet over the past month or expected change in diet during the study

Additional Information

Official title The Study of Soy Isoflavones in Asthma
Principal investigator Lewis J Smith, MD
Description Asthma is a common disease that has a major impact on morbidity and health care costs. Although the prevalence and severity of asthma have increased over the last several decades, the specific causes remain unknown. One possible mechanism is a change in diet. Yet, epidemiological and interventional studies designed to identify a key nutrient or antioxidant vitamin that may be responsible for the increase in disease severity have produced inconsistent results. A recent pilot study showed a soy isoflavone supplement reduces exhaled nitric oxide (FeNO) and ex vivo LTC4 synthesis in patients with inadequately controlled asthma. This clinical trial is designed to test the novel hypothesis that dietary supplementation with soy isoflavones is an effective treatment in patients with poorly controlled asthma. The study will include 380 patients with low dietary soy intake, 12 years of age or older, who are taking either inhaled corticosteroids or leukotriene modifiers and have inadequately controlled asthma. Participants will be randomly assigned to treatment with either a soy isoflavone supplement (containing genistein, daidzein and glycitein; 100 mg daily of the glycoside forms) or placebo for six months. The results of this trial will increase understanding of the role of diet in asthma; could identify a novel, safe and relatively inexpensive treatment for patients with asthma; and potentially will have a substantial impact on public health in the United States.
Trial information was received from ClinicalTrials.gov and was last updated in June 2012.
Information provided to ClinicalTrials.gov by American Lung Association Asthma Clinical Research Centers.